Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EDT.TO
- Price
- 1.41
- Stock movement down
- -0.05 (-3.42%)
- Company name
- Spectral Med Inc
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Diagnostics & Research
- Market cap
- 407.69M
- Ent value
- 478.58M
- Price/Sales
- 150.72
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 20.45%
- 1 year return
- 176.47%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2026-01-16
DIVIDENDS
EDT.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 150.72 |
| Price to Book | - |
| EV to Sales | 176.93 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 289.14M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -0.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.89M |
| Net receivables | 433.00K |
| Total current assets | 7.25M |
| Goodwill | 0.00 |
| Intangible assets | 347.00K |
| Property, plant and equipment | 524.00K |
| Total assets | 8.13M |
| Accounts payable | 2.98M |
| Short/Current long term debt | 20.96M |
| Total current liabilities | 67.37M |
| Total liabilities | 76.79M |
| Shareholder's equity | -68.66M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.49 |
| Daily high | 1.50 |
| Daily low | 1.39 |
| Daily Volume | 57K |
| All-time high | 39.13 |
| 1y analyst estimate | 3.10 |
| Beta | 0.27 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 19 Dec 2011 |
| Next earnings date | 26 Mar 2026 |
Downside potential
Loading...
Downside potential data
| EDT.TO | S&P500 | |
| Current price drop from All-time high | -96.40% | -0.42% |
| Highest price drop | -98.80% | -19.00% |
| Date of highest drop | 19 Dec 2024 | 8 Apr 2025 |
| Avg drop from high | -97.62% | -2.50% |
| Avg time to new high | - | 6 days |
| Max time to new high | 318 days | 89 days |
COMPANY DETAILS
Marketcap
407.69M
Marketcap category
Small-cap
Description
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Employees
29
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Spectral Medical (EDT.TO), Friday said it is compiling its pre-market approval (PMA) submission pack
November 7, 2025
PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactionsCompany to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE NE...
November 7, 2025
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
September 29, 2025
Spectral Medical (EDT.TO) on Tuesday said newly published findings of an observational study showed
September 16, 2025
New Study Strengthens Rationale for Spectral’s PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient GroupTORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (...
September 16, 2025
Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranost...
September 8, 2025
TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
August 25, 2025
The device was first approved in Europe more than 20 years ago in 1994 by Toray Industries.
August 13, 2025
Spectral Medical (EDT.TO) and Vantive on Tuesday afternoon released top-line results from the Tigris
August 12, 2025
Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality Pooled absolute risk reduction of 8.3%; Relative risk reduction of 18% Key secondary en...
August 12, 2025
Next page